Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 9k
21 October 2019
Question for written answer
to the Commission
Rule 138
Eric Andrieu
 Subject: Bisphenol B, a substitute for bisphenol A, and safeguarding consumer health

Bisphenol B would appear to produce endocrine effects similar to those of bisphenol A, the first chemical substance to be classified at EU level as a human endocrine disruptor. Bisphenol B is now used in place of bisphenol A and bisphenol S for some purposes, and traces of it have been found in some populations exposed to imported products, including goods from the USA, where Bisphenol B is authorised. Just like bisphenol A, this molecule is believed to interfere with numerous endocrine pathways. It could therefore have an effect on certain hormones, and thus interfere with the way our bodies process food, sleep, reproduce or develop embryos. It would thus appear to pose a clear and present danger to human health.

What view Commission does the Commission take on bisphenol B? Does it agree that we need to:

Regulate this substance?

Suspend – in view of the precautionary principle – the sale of products containing bisphenol B until such time as further analyses are carried out, in order to safeguard the health of Europe’s citizens?

Original language of question: FR
Last updated: 21 November 2019Legal notice